CytomX Therapeutics (CTMX) Times Interest Earned (2014 - 2026)
CytomX Therapeutics' (CTMX) quarterly Times Interest Earned came in at -$1117.3 in Q4 2025, down 1024605.12% YoY from N/an in Q4 2024, and down 35328.72% on a QoQ basis from -$3.15 in Q3 2025.
CytomX Therapeutics (CTMX) Times Interest Earned (2014 - 2026) Analysis & Trends
CytomX Therapeutics (CTMX) has 12 years of Times Interest Earned data on file, last reported at -$1117.3 in Q4 2025.
- Quarterly Times Interest Earned fell 1024605.12% year-over-year to -$1117.3 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was -$49.39 (down 800.56% YoY) and the FY2025 annual result came in at -$0.91, down 689.76% from the prior year.
- Times Interest Earned slipped to -$1117.3 in Q4 2025, from -$3.15 in the prior quarter.
- In the past five years, Times Interest Earned ranged from a high of $4.44 in Q1 2025 to a low of -$1117.3 in Q4 2025.
- A 5-year average of -$71.65 and a median of -$3.64 in 2022 frame the typical range for Times Interest Earned.
- Annual changes were most pronounced in 2024 — Times Interest Earned surged 3257.46% — and 2025, when it plunged 1024605.12%.
- Tracing CTMX's Times Interest Earned over 5 years: stood at -$26.66 in 2021, then surged by 84.5% to -$4.13 in 2022, then soared by 99.92% to -$0.0 in 2023, then surged by 3257.46% to $0.11 in 2024, then sank by 1024605.12% to -$1117.3 in 2025.
- The last three Times Interest Earned figures came in at -$1117.3 (Q4 2025), -$3.15 (Q3 2025), and -$0.25 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | CytomX Therapeutics | 732.14 Mn | 401.86 Mn | - | -4.17 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.17 |
| Dec 31, 2025 | -1,117.28 |
| Sep 30, 2025 | -3.15 |
| Jun 30, 2025 | -0.25 |
| Mar 31, 2025 | 4.44 |
| Dec 31, 2024 | 0.11 |
| Sep 30, 2024 | 1.00 |
| Jun 30, 2024 | -2.11 |
| Mar 31, 2024 | 2.99 |
| Dec 31, 2023 | 0.00 |
| Sep 30, 2023 | 1.12 |
| Dec 31, 2022 | -4.13 |
| Sep 30, 2022 | -37.37 |
| Jun 30, 2022 | -25.86 |
| Mar 31, 2022 | -34.89 |
| Dec 31, 2021 | -26.66 |
| Sep 30, 2021 | -24.38 |
| Jun 30, 2021 | -4.79 |
| Mar 31, 2021 | -18.38 |
| Dec 31, 2020 | -18.91 |